UCB and Novartis Join to Advance Oral Therapy Now in Phase 2 Trial

UCB and Novartis Join to Advance Oral Therapy Now in Phase 2 Trial

313425

UCB and Novartis Join to Advance Oral Therapy Now in Phase 2 Trial

UCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the alpha-synuclein protein now in a Phase 2 clinical trial enrolling people with Parkinson’s disease. The agreement also includes an option to co-develop UCB7853 — an antibody against alpha-synuclein — currently in Phase 1 testing as a possible Parkinson’s treatment. “This partnership has the potential to be transformational for people living with Parkinson’s disease, as it will combine…

You must be logged in to read/download the full post.